Literature DB >> 25783947

Natriuretic peptides for risk stratification of patients with valvular aortic stenosis.

Vishal Parikh1, Candice Kim1, Robert J Siegel1, Reza Arsanjani1, Florian Rader2.   

Abstract

Entities:  

Keywords:  aortic valve stenosis; natriuretic peptides; prognosis; ventricular remodeling

Mesh：

Substances：

Year:  2015        PMID： 25783947     DOI： 10.1161/CIRCHEARTFAILURE.114.001649

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN： 1941-3289            Impact factor:   8.790


× No keyword cloud information.
  7 in total

1.  Alendronate slows down aortic stenosis progression in osteoporotic patients: An observational prospective study.

Authors:  Gholamhossein Alishiri; Kiyan Heshmat-Ghahdarijani; Mohammad Hashemi; Reihaneh Zavar; Maryam Moshkani Farahani
Journal:  J Res Med Sci       Date:  2020-06-30       Impact factor: 1.852

2.  Elevation of B-Type Natriuretic Peptide at Discharge is Associated With 2-Year Mortality After Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis: Insights From a Multicenter Prospective OCEAN-TAVI (Optimized Transcatheter Valvular Intervention-Transcatheter Aortic Valve Implantation) Registry.

Authors:  Kazuki Mizutani; Masahiko Hara; Shinichi Iwata; Takashi Murakami; Toshihiko Shibata; Minoru Yoshiyama; Toru Naganuma; Futoshi Yamanaka; Akihiro Higashimori; Norio Tada; Kensuke Takagi; Motoharu Araki; Hiroshi Ueno; Minoru Tabata; Shinichi Shirai; Yusuke Watanabe; Masanori Yamamoto; Kentaro Hayashida
Journal:  J Am Heart Assoc       Date:  2017-07-14       Impact factor: 5.501

3.  Associations of brain-natriuretic peptide, high-sensitive troponin T, and high-sensitive C-reactive protein with outcomes in severe aortic stenosis.

Authors:  Andreas Auensen; Amjad Iqbal Hussain; Ragnhild Sørum Falk; Marte Meyer Walle-Hansen; Jorun Bye; Kjell Ingar Pettersen; Pål Aukrust; Thor Ueland; Lars Lysgaard Gullestad
Journal:  PLoS One       Date:  2017-06-12       Impact factor: 3.240

4.  Is elevation of N-terminal pro-B-type natriuretic peptide at discharge associated with 2-year composite endpoint of all-cause mortality and heart failure hospitalisation after transcatheter aortic valve implantation? Insights from a multicentre prospective OCEAN-TAVI registry in Japan.

Authors:  Kazuki Mizutani; Masahiko Hara; Mana Nakao; Tsukasa Okai; Keiko Kajio; Takashi Murakami; Toshihiko Shibata; Minoru Yoshiyama; Toru Naganuma; Futoshi Yamanaka; Akihiro Higashimori; Norio Tada; Kensuke Takagi; Motoharu Araki; Hiroshi Ueno; Minoru Tabata; Shinichi Shirai; Yusuke Watanabe; Masanori Yamamoto; Kentaro Hayashida
Journal:  BMJ Open       Date:  2018-08-17       Impact factor: 2.692

5.  B-type natriuretic peptide is associated with remodeling and exercise capacity after transcatheter aortic valve replacement for aortic stenosis.

Authors:  Kimi Sato; Arnav Kumar; Amar Krishnaswamy; Stephanie Mick; Milind Y Desai; Brian P Griffin; Samir R Kapadia; Zoran B Popović
Journal:  Clin Cardiol       Date:  2018-12-31       Impact factor: 2.882

6.  Relationship between B-type natriuretic peptide and invasive haemodynamics in patients with severe aortic valve stenosis.

Authors:  Micha T Maeder; Lukas Weber; Peter Ammann; Marc Buser; Niklas F Ehl; Marc Gerhard; Roman Brenner; Philipp K Haager; Francesco Maisano; Hans Rickli
Journal:  ESC Heart Fail       Date:  2020-01-29

7.  Prognostic relevance of B-type natriuretic peptide in patients with moderate mixed aortic valve disease.

Authors:  Hirokazu Onishi; Toru Naganuma; Masaki Izumo; Toru Ouchi; Haruhito Yuki; Satoru Mitomo; Sunao Nakamura
Journal:  ESC Heart Fail       Date:  2022-05-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.